8-K
Liminatus Pharma Enters into Private Placement Agreement for $650,002.50
8-K
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
8-K
Liminatus Pharma, Inc. Announces 1-for-50 Reverse Stock Split
8-K
Liminatus Pharma, Inc. Announces Results of 2026 Annual Meeting of Stockholders
8-K
Liminatus Pharma, Inc. Reports Stockholders’ Equity Exceeding Nasdaq Compliance Threshold Following Merger
8-K
Liminatus Pharma Faces Potential Nasdaq Delisting Following Bid Price Deficiency
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedi...